Kereos is developing nanotechnologies to identify tumors that measure just 1 mm in diameter, then kill them with a tiny but precise amount of a chemotherapy drug.

The biomarker being used is a group of four proteins that signal that a tumor needs to recruit blood vessels, a process called angiogenesis.